Expert Ratings For United Therapeutics
Expert Ratings For United Therapeutics
联合疗法的专家评级
During the last three months, 7 analysts shared their evaluations of United Therapeutics (NASDAQ:UTHR), revealing diverse outlooks from bullish to bearish.
在过去的三个月中，7位分析师分享了他们对联合疗法（纳斯达克股票代码：UTHR）的评估，揭示了从看涨到看跌的不同前景。
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
下表概述了他们最近的评级，简要介绍了过去30天中不断变化的情绪，并将其与前几个月进行了比较。
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $310.43, with a high estimate of $400.00 and a low estimate of $240.00. This current average has increased by 5.05% from the previous average price target of $295.50.
分析师对12个月目标股价的评估提供了更多见解，显示平均目标价为310.43美元，最高估计为400.00美元，低估值为240.00美元。目前的平均价格较之前的平均目标价295.50美元上涨了5.05％。
Breaking Down Analyst Ratings: A Detailed Examination
分解分析师评级：详细审查
The perception of United Therapeutics by financial experts is analyzed...
通过分析师最近的行动...
登录免费看全文
登录/注册